Leading Belgian Teaching Hospital Selects RayStation
News Aug 10, 2016
AZ Sint-Jan Brugge – Oostende AV Hospital has selected RayStation as the sole treatment planning system for the expanding radiation therapy department at its campus in Bruges. RayStation will replace the department’s existing system and will support treatment planning for existing linacs, as well as two newly purchased machines.
RayStation will enable the department to simplify and optimize its workflows, and to take strides in adaptive planning. The agreement includes, amongst other things, the full RayStation adaptive radiation therapy package and multi-criteria optimization (MCO). Licenses have been purchased for nine concurrent users.
Geertrui Demeestere, M.D., head of the radiation therapy department at the campus in Bruges, says: “RayStation’s MCO capabilities will give us a simpler way to create optimized plans that match our clinical objectives for each individual case. The contouring tools are excellent and will save significant time while increasing accuracy.”
Bert Bakelandt, head of physics at AZ Sint-Jan – Oostende AV Hospital, Bruges, says: “Adaptive radiation therapy is an important approach for us going forward and RayStation gives us all the tools we need in a single system. Features such as rapid calculation speed and highly accurate deformable registration will enable a fast and effective adaptive therapy workflow. RaySearch has the technical expertise to tailor the installation to our requirements, including implementation of a VMware Horizon virtual desktop infrastructure solution. RayStation’s scripting tools offer the possibility to automate and optimize the treatment planning workflow.”
Johan Löf, CEO of RaySearch Laboratories, says: “We are very pleased to provide the complete treatment planning solution for AZ Sint-Jan – Oostende AV Hospital. Adaptive radiation therapy is a key focus for us, and we have designed RayStation from the outset to support this approach. We look forward to a collaboration that will bring the benefits of adaptive therapy to more patients in Bruges.”
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers say they have identified that target - an enzyme called PPT1 - opening up a new pathway for potential cancer treatments.READ MORE